ORDER A TEST
PORTALS

Economic Evaluation of the 70-gene Prognosis-Signature (MammaPrint®) in Hormone Receptor-Positive, Lymph Node-Negative, Human Epidermal Growth Factor Receptor Type 2-Negative Early Stage Breast Cancer in Japan

PUBLICATION: Breast Cancer Res Treat. 2012 Jun;133(2):759-68. doi: 10.1007/s10549-012-1979-7. AUTHORS: Read More

2024-03-25T10:52:27-04:00June 1st, 2012|Evidence, Healthcare Economics, MammaPrint, Other|

Impact of Mammographic Screening on the Detection of Good and Poor Prognosis Breast Cancers

PUBLICATION: Breast Cancer Res Treat. 2011 Dec;130(3):725-34. doi: 10.1007/s10549-011-1748-z. Epub Read More

2024-03-25T10:55:45-04:00December 2nd, 2011|Evidence, MammaPrint, Other|

The 70-gene Signature as a Response Predictor for Neoadjuvant Chemotherapy in Breast Cancer

PUBLICATION: Breast Cancer Res Treat. 2010 Feb;119(3):551-8. doi: 10.1007/s10549-009-0333-1. Epub Read More

2024-03-25T11:03:35-04:00February 1st, 2010|Evidence, MammaPrint, Neoadjuvant|

The 70-gene Prognosis-Signature Predicts Disease Outcome in Breast Cancer Patients with 1-3 Positive Lymph Nodes in an Independent Validation Study

PUBLICATION: Breast Cancer Res Treat. 2009 Jul;116(2):295-302. doi: 10.1007/s10549-008-0130-2. Epub Read More

2024-03-25T11:09:15-04:00July 27th, 2009|Evidence, MammaPrint, Other, Validation|
Go to Top